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TIIVISTELMÄ 
Tutkimuksen tausta ja tavoitteet: Eturauhassyöpä on yleinen syöpäsairaus, joka 
koskettaa maailmanlaajuisesti miljoonia miehiä. Sairauden taustalla olevat 
molekulaariset mekanismit ovat yhä huonosti tunnettuja. Genomin kopiolukumuutokset 
ovat yleisiä eturauhassyövässä, ja eräs toistuva monistuma sijaitsee kromosomissa 
9p13.3. Tämän vastikään löydetyn monistuman tiedetään olevan yhteydessä 
korkeampaan PSA-arvoon sekä lyhyempään progressiovapaaseen elinaikaan 
prostatektomiapotilailla, mikä viittaa siihen, että monistuman alueella saattaa sijaita yksi 
tai useampia tuntemattomia onkogeeneja. UBAP2 on eräs 9p13.3 monistuman 
potentiaalinen kohdegeeni. Tämän tutkimuksen tavoitteena oli kloonata UBAP2-geeni ja 
tutkia sen yli-ilmentymisen mahdollisia vaikutuksia eturauhassyöpäsolujen 
proliferaatioon.  
Tutkimusmenetelmät: UBAP2 kloonattiin TOPO-TA-kloonausmenetelmää käyttäen 
pCMV-Sport6-ilmentämisvektoriin. PC-3- ja LNCaP-eturauhassyöpäsoluja 
transfektoitiin väliaikaisesti UBAP2-geenin eri varianteilla ja solujen proliferaatiota 
tutkittiin AlamarBlue-määritysmenetelmällä sekä mikroskoopin ja digitaalikuva-
analyysin avulla. UBAP2-lähetti-RNA:n yli-ilmentyminen varmistettiin 
kvantitatiivisella käänteiskopiointipolymeraasiketjureaktiolla, ja proteiinitason yli-
ilmentyminen varmistettiin immunosytokemiallisesti. 
Tutkimustulokset: Tutkimuksessa kloonattiin onnistuneesti täysimittainen UBAP2-
geeni. Tämän lisäksi tutkimuksessa löydettiin useita ennestään tuntemattomia UBAP2-
geenin silmikointivariantteja. Käänteiskopiointipolymeraasiketjureaktiosta saatujen 
tulosten perusteella UBAP2-geenillä transfektoidut eturauhassyöpäsolut ilmensivät 
UBAP2-lähetti-RNA:ta korkealla tasolla. Proteiinitasolla puolestaan osa 
transfektoiduista solupopulaation soluista ilmensi UBAP2-proteiinia korkealla tasolla, 
kun taas osa soluista ilmensi sitä hyvin vähän. Täysimittaisen UBAP2:n yli-
ilmentäminen lisäsi hieman sekä PC-3- että LNCaP-solujen proliferaatiota, mutta 
vaikutus ei ollut tilastollisesti merkittävä. 
Johtopäätökset: UBAP2-geenin transkriptioon ja silmikointiin liittyy paljon 
monimutkaisia mekanismeja. Vaikka tämän tutkimuksen tulosten perusteella UBAP2-
geenin yli-ilmentämisellä ei ole tilastollisesti merkittävää vaikutusta 
eturauhassyöpäsolujen proliferaatioon, näiden tulosten perusteella ei voida täysin sulkea 
pois sitä mahdollisuutta, että UBAP2 on 9p13.3-monistuman kohdegeeni. 
Lisätutkimuksia tarvitaan selvittämään UBAP2-geenin toimintaa sekä sen yli-
ilmentämisen vaikutuksia eturauhassyövässä.  
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ABSTRACT 
Background and aims: Prostate cancer is a common malignancy affecting millions of 
men worldwide. The molecular mechanisms involved in prostate cancer are poorly 
understood. Genomic copy-number alterations are common in prostate cancer and one 
recurrently amplified region is 9p13.3. This recently identified amplification has been 
found to be associated with higher PSA-level and poor progression-free survival in 
prostatectomy treated patients, which indicates that the region harbors one or more 
novel oncogenes. UBAP2 is one potential target gene of 9p13.3 gain. The aim of this 
study was to clone UBAP2 gene and to investigate whether its overexpression would 
affect the proliferation of prostate cancer cells.  
Methods: UBAP2 gene was cloned with TOPO-TA cloning to pCMV-Sport6 
expression vectors. PC-3 and LNCaP prostate cancer cells were transiently transfected 
with different UBAP2 variants and their proliferation was assessed by AlamarBlue 
assay and by microscopy and digital image analysis. UBAP2 mRNA overexpression 
was verified by using RT-qPCR analysis. Overexpression at the protein level was 
verified by using immunocytochemistry. 
Results: In this study, the cDNA for full-length UBAP2 gene was successfully cloned. 
In addition, we identified multiple novel splice variants of UBAP2. According to RT-
qPCR results, prostate cancer cells transfected with UBAP2 expressed its mRNA at high 
levels. At the protein level, a subset of the transfected cells expressed UBAP2 at a high 
level, while the others expressed it at a very low level only. Overexpression of the full-
length UBAP2 slightly increased the proliferation of PC-3 and LNCaP cells, but the 
differences were statistically insignificant.  
Conclusion: There are many distinctive features associated with transcription and 
splicing of UBAP2. Although the results of this study suggest that UBAP2 
overexpression has no statistically significant effects on the proliferation of prostate 
cancer cells, we cannot rule out the possibility that UBAP2 is the target gene of 9p13.3 
amplification. Further investigations have to be carried out to determine the function of 
UBAP2 and to clarify the role of its increased expression to prostate cancer.  
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ABBREVIATIONS 
aCGH  Array CGH 
AKT  V-akt murine thymoma viral oncogene homolog 
AR  Androgene receptor 
ARL11  ADP-ribosylation factor-like 11 
ATCC  American Type Culture Collection 
BCAS3  Breast carcinoma amplified sequence 3 
C9orf25  Chromosome 9 open reading frame 25 
cCGH  Chromosomal CGH 
CCND2  Cyclin D2 
CCNL1  Cyclin L1 
CD72  Cluster of differentiation 72 
CDH13  Cadherin 13 
CGH  Comparative genomic hybridization 
CllD7  Chronic lymphocytic leukemia deletion gene 7 
CMV  Cytomegalovirus 
CRPC  Castration resistant prostate cancer 
CYP1B1  Cytochrome P450, family 1, subfamily B, polypeptide 1 
DCTN3  Dynactin subunit 3 
ECT2  Epithelial cell transforming sequence 2 oncogene 
ERBB2  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
ERG  Ets related gene 
ESR1/2  Estrogen receptor 1/2 
ETS  E twenty-six 
ETV1/4/5  Ets variant 1/4/5 
FISH  Fluorescence in situ hybridization 
FKBP5  FK506 binding protein 5 
GALT  Galactose-1-phosphate uridylyltransferase 
GMPS  Guanine monophosphate synthetase 
HER2  Human Epidermal Growth Factor Receptor 2 
HERPUD1 homocysteine-inducible endoplasmic reticulum stress-
inducible ubiquitin-like domain member 1 
HGPIN  High-grade PIN 
Hox  Homeobox 
IGF2  Insulin-like growth factor 2 
LB  Luria Broth 
LINE1  Long interspersed nuclear element 1 
MAF  v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
MLF1  Myeloid leukemia factor 1 
MYC  v-myc myelocytomatosis viral oncogene homolog 
NDRG1  N-myc downstream regulated 1 
NGS  Next-generation sequencing 
NKX3.1  NK3 homeobox 1 
PC-3  PC-3 human prostate cancer cell line 
PI3K  Phosphoinositide 3-kinase 
PIGO  Phosphatidylinositol glycan anchor biosynthesis, class O 
PIN  Prostatic intraepithelial neoplasia 
PLAU  Plasminogen activator, urokinase 
PSA  Prostate specific antigen 
PTEN  Phosphatase and tensin homolog 
PTES  Post transcriptional exon shuffling 
RFP2  Ret finger protein 2 
RGC32  Response gene to complement 32 
RUSC2  RUN and SH3 domain containing 2 
SKIL  SKI-like oncogene 
SLC45A3  Solute carrier family 45 member 3 
TBP  TATA-binding protein 
TLOC1/SEC62 Translocation protein 1/ SEC62 homolog 
TMPRSS2  Transmembrane protease, serine 2 
TP53  Tumor protein 53 
UBA  Ubiquitin-associated 
UBAP2  Ubiquitin-associated protein 2 
UBE2R2  Ubiquitin-conjugating enzyme E2R 2 
UNC13B  Unc-13 homolog B 
VCP  Valosin containing protein
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1. INTRODUCTION 
Prostate cancer is the second most common cancer of the men worldwide and the most 
common cancer among men living in western countries (Center et al. 2012). As the life 
expectancy is increasing in most countries and the prostate cancer incidence increases 
with the age, it is anticipated that the number of prostate cancer cases will continue to 
increase (Center et al. 2012). Worldwide, prostate cancer is the sixth leading cause of 
cancer-related death in men, although mortality is decreasing in many developed 
countries, mainly because of earlier diagnosis and improved treatment (Jemal et al. 
2011).  
Prostate cancer is a highly heterogeneous disease, both clinically and genetically (Boyd, 
Mao & Lu 2012). The majority of prostate tumors are slow-growing, metastasize rarely 
and they are not likely to cause death. However, some prostate cancers behave 
aggressively; they metastasize quickly and eventually progress to castration resistant 
prostate cancer (CRPC) with limited treatment options. One of the key questions is how 
to distinguish aggressive and indolent prostate cancers at an early stage. One strategy is 
to identify and detect biomarkers or genetic alterations that are associated with an 
aggressive disease. Some of these alterations are also potential therapeutic targets. 
Prostate cancer is characterized by multiple genomic alterations, including both point 
mutations and chromosomal rearrangements (Boyd, Mao & Lu 2012). As prostate 
cancer is genetically a highly heterogeneous disease, patients typically harbor a diverse 
and unique set of alterations, which is affected also by geographic and ethnic factors. 
Generally, somatic point mutations seem to be rare relative to other cancers, while 
chromosomal copy number alterations are more frequently found (Taylor et al. 2010). 
Deletions in at least chromosomes 2q, 5q, 6q, 8p, 10q, 13q, 16q, 18q and 21q, and gains 
in chromosomes 3q, 7q, 8q, 9p, 17q and Xq are recurrently observed in prostate cancer 
(Cheng et al. 2012). These regions harbor many known cancer associated genes, and 
new genes are continuously identified. 
Recurrent gain on chromosome 9p13.3 has previously been identified, and according to 
previous studies even 10% and 32% of prostatectomy treated patients harbor high-level 
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and low-level 9p13.3 amplifications, respectively (Leinonen 2007). In the same study, 
9p13.3 gain was found to be associated with higher PSA-value and poor progression-
free survival in prostatectomy treated patients (Leinonen 2007). Although the 9p13.3 
region harbors multiple potential candidate genes whose expression is known to 
correlate with increased copy number, no cancer associated genes have been identified 
from this region (Leinonen 2007). Identification of the target gene of the 9p13.3 
amplification might provide a new prognostic marker for prostate cancer and help to 
understand the molecular mechanisms underlying prostate cancer progression.  
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2. REVIEW OF LITERATURE 
2.1 Prostate 
Prostate gland is a part of male reproductive system. It accounts for the production and 
transportation of sperm and secretion of male sex hormones. The main function of the 
prostate is to store and secrete slightly alkaline, milky prostatic fluid. This fluid 
constitutes about half of the semen volume, along with spermatozoa and seminal vesicle 
fluid. Prostate gland is located below the bladder, as shown in the Figure 1. 
 
 
 
 
 
Figure 1. The prostate gland. The image shows the anatomical location of the 
prostate. Image modified from http://centegra.org/wp-content/uploads/page/Male_ 
Prostate_Anatomy_Sagital_View_-_low_res.jpg. 
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During the embryogenesis, the prostate is derived from the primitive endoderm, which 
first differentiates to cloaca. In humans, as well as in other placental mammals, the 
cloaca separates to digestive outlet and urogenital sinus, which then segments into the 
urinary bladder and the urethra. Prostate develops via the proliferation of epithelial buds 
from the urogenital sinus epithelium. These buds invade according to particular pattern, 
which directs the future development of distinct prostate zones (or lobes). Later, 
urogenital sinus mesenchymal cells differentiate into stromal elements. Prostate 
budding occurs during the 10
th
 week of embryogenesis. (Berman et al. 2012) 
Androgen receptor (AR) signaling acts on the mesenchyme and is the primary 
motivating force behind prostate development (Berman et al. 2012). However, AR 
signaling only affects the timing of events, not their location. Mechanisms that direct 
the precise locations of prostate epithelial buds are not fully understood, but are likely to 
be related to paralogous homeobox (Hox) genes, as they coordinate similar processes in 
various tissues. It is also know that homozygous mutations in Hox genes can result in 
changes in prostatic branching patterns (Podlasek, Duboule & Bushman 1997).  
The adult prostate is a complex tubule-alveolar gland, and the regional anatomy of the 
human prostate has been widely debated during the last century. Originally prostate was 
classified into lobes, but nowadays this concept is commonly replaced by zonal model 
(Timms 2008). According to this model, prostate is classified into anterior, peripheral, 
central and transitional zones that all have their own architectural features. The prostate 
is composed of epithelial compartment and stroma. The epithelial compartment consists 
of basal epithelial cells, intermediate cells, neuroendocrine cells and luminal secretory 
cells. The stromal compartment, in turn, serves a structural support consisting of 
connective tissue, smooth muscle cells and fibroblasts. (Berman et al. 2012) 
While androgen signaling is important during development of the prostate in 
embryogenesis, it is also important for the growth, maintenance and secretory function 
of prostate during the different stages of human life. 
2.1.1 Non-malignant prostate diseases 
Prostatitis, inflammation of the prostate gland, is the most commons urologic problem 
of men younger than 50 years of age. Prostatitis can be caused by bacterial infection, 
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usually caused by Escherichia coli, and the infection can be either acute or chronic. 
Bacterial prostatitis is cured primarily by antibiotics. (Benway, Moon 2008) However, 
the vast majority, even 90%, of prostatitis cases are non-bacterial. This condition is 
characterized by pain or discomfort in the pelvic region, urinary symptoms and/or 
sexual dysfunction, and it can significantly diminish the quality of life. Although the 
etiology of non-bacterial prostatitis is unclear, it is known that factors like heredity 
background, infections, hormone imbalance, intraprostatic reflux, immunological or 
allergic triggers and psychological traits can incite it. (Anothaisintawee et al. 2011) The 
management of non-bacterial prostatitis is often quite complex, and applied treatments 
include α-blockers, antibiotics or anti-inflammatory medications (Thakkinstian et al. 
2012). In addition to pharmacological treatments, other methods like prostatic massage, 
electromagnetic stimulation, physical therapy and thermotherapy are also used for the 
management of prostatitis (Schiller, Parikh 2011). 
Benign prostatic hyperplasia (BPH) is a common condition in which the size of the 
prostate gland is increased. It is a common disease among ageing men, and it is 
associated with multiple bothersome lower urinary tract symptoms, such as frequent 
urination and the sensation of incomplete bladder emptying. BPH can be treated 
surgically or by drugs like α1-adrenergic receptor blockers and 5-α-reductase inhibitors. 
Also other therapies are used. (Shrivastava, Gupta 2012) However, BPH does not give 
rise to a malign prostate disease. 
BPH and prostate cancer form in different areas of the prostate; the former develops 
from the transitional zone or central zone of the gland, while the latter develops from 
the peripheral zone (De Nunzio et al. 2011). However, benign prostatic hyperplasia and 
prostate cancer share many significant anatomic, pathologic, genetic and 
epidemiological features. Many studies have focused on the relationship between BPH 
and the development of prostate cancer, but it is still unclear. (Alcaraz et al. 2009) It has 
been suggested that chronic prostatitis may be involved in the development and 
progression of both BPH and prostate cancer (De Nunzio et al. 2011). 
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2.2 Prostate cancer 
2.2.1 Epidemiology 
Prostate cancer is the most common malignancy and the third most common cause of 
death from cancer of men in the developed countries (Jemal et al. 2011). In Finland, 
almost 5000 new prostate cancer cases are diagnosed annually, and nearly 900 men die 
every year due to this cancer. Hence, prostate cancer is the second most common cause 
of death from cancer of men in Finland. Prostate cancer incidence has increased during 
the past decades, but at the same time prostate cancer specific mortality has stayed 
relatively stable. (Finnish Cancer Registry, 2012). Similar trends can be seen in other 
Western countries as well (Center et al. 2012, Brawley 2012, Crawford 2003).  
The increase of the prostate cancer incidence in developed countries mainly results from 
increased life expectancy, advanced diagnostic methods and the generalization of PSA 
screenings (Center et al. 2012). Prostate cancer affects mostly old men; over 70% of 
prostate cancer cases are diagnosed in men over 65 years of age, and the disease is only 
relatively rarely diagnosed in men less than 50 years of age (Crawford 2003). As the 
average life expectancy in many developing countries is less than 65 years, it is easy to 
understand why prostate cancer is not as common in developing as in developed 
countries (WHO World Health Statistics 2012). 
2.2.2 Pathogenesis 
Prostate cancer arises from glandular epithelium, most commonly from the peripheral 
zone. At first, there will appear prostatic intraepithelial neoplasia (PIN) lesions that are 
progressive abnormalities with genotypes and phenotypes that are an intermediate 
between those of benign prostatic epithelium and prostate cancer. PIN lesions are 
characterized by the proliferation of secretory cells with significant cytological 
abnormalities within the prostate glands and acini. These cells typically have an 
increased nuclear/cytoplasmic ratio and prominent nucleoli. In contrast to prostate 
adenocarcinoma, in PIN lesions the basal cell layer is retained, while it is absent in 
cancer. (Bostwick, Cheng 2012, Klink et al. 2012) PIN lesions are classified into low 
grade (LGPIN) and high grade (HGPIN) lesions according to cytological characteristics 
(Goeman et al. 2003). The hypothesis that HGPIN is a precursor of prostate cancer is 
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widely accepted and a lot of evidence supporting it has been presented. The incidence of 
both HGPIN and prostate cancer increase with age, and the frequency and the severity 
of HGPIN increases in the presence of prostate cancer. HGPIN shares many features 
with prostate cancer and the transition of HGPIN to prostate cancer can be observed 
morphologically. Moreover, both HGPIN and prostate cancer have similar genetic and 
molecular features. (Montironi et al. 2007) 
PIN lesions are a common finding in prostate biopsies; the total incidence of isolated 
PIN averages 9% in United States, which represents about 115 000 new cases each year 
(Bostwick, Cheng 2012). The frequency of cancer detection on repeat biopsy after 
diagnosis of HGPIN is about 20-30% (Schoenfield et al. 2007, Gallo et al. 2008, 
Roscigno et al. 2004, Epstein, Herawi 2006, Herawi et al. 2006). This frequency is not 
far from the frequency of cancer detection after diagnosis of benign prostatic 
hyperplasia, which is about 20% (Montironi et al. 2007, Gallo et al. 2008). In studies 
published before the year 2000, cancer detection rate following HGPIN diagnosis was 
even 36%. The decrease in the percentage may result from increased biopsy core 
number routinely sampled, as previously HGPIN findings on needle biopsies were often 
representing sampling problems with carcinomas nearby. (Klink et al. 2012) However, 
the predictive value of isolated HGPIN can be higher in two situations; if HGPIN is 
adjacent to atypical glands or in case of multifocal HGPIN (Schoenfield et al. 2007, 
Roscigno et al. 2004). 
2.2.3 Risk factors 
Age, race and positive family history are the most important prostate cancer risk factors. 
Also some other factors, like over-weight, smoking, taller height and high α-linolenic 
acid intake have been found to be associated with high prostate cancer risk 
(Giovannucci et al. 2007). In United States, prostate cancer incidence rates have 
significantly increased among men younger than 50 years old during the last decade. At 
the same time the incidence rates among men older than 70 years have decreased, which 
suggests that these changes result from earlier diagnosis. (Li et al. 2012) 
A family history of prostate cancer is known to be associated with increased risk of 
prostate cancer diagnosis (Thomas et al. 2012). According to some studies, first-degree 
relatives of prostate cancer patients have a 2,5-fold relative risk of prostate cancer, 
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while first-degree relatives of two prostate cancer patients have a 3,5-fold relative risk. 
The risk is even higher, if prostate cancer was diagnosed before the age 60, and it 
decreases with age (Johns, Houlston 2003). It has also been found out that men with 
first-degree relatives affected by prostate cancer are diagnosed and die at earlier age 
than men without relatives affected by prostate cancer (Brandt et al. 2009). 
African American males have over 2-fold risk of prostate cancer and also have over 
2-fold prostate cancer specific mortality when compared to Caucasian males in the 
United States (American Cancer Society 2012). The reason for this is poorly 
understood, but lower income among the African American population may affect the 
higher mortality (Taksler, Keating & Cutler 2012).  
According to a large recent cohort study, current smokers have an increased risk of fatal 
prostate cancer, but a decreased risk of non-advanced prostate cancer (Watters et al. 
2009). Similarly, former smoking was associated with decreased risk of non-advanced 
prostate cancer. However, the association shown in this study were not very strong.  
(Watters et al. 2009). In a prospective observational study within North American 
prostate cancer patients, it was observed that smoking at the time of cancer diagnosis 
was associated with increased overall mortality and cardiovascular disease and prostate 
cancer specific mortality and cancer recurrence (Kenfield et al. 2011). It seems that 
smoking does not actually increase the risk of prostate cancer diagnosis, but it seems to 
increase the probability to dying due to prostate cancer. 
Alcohol consumption is known to be a risk factor of numerous cancers. In a large cohort 
study within the North American population, the risk of non-advanced prostate cancer 
was 25% higher for men consuming at least 6 servings of alcohol daily, 19% higher for 
men consuming 3-6 serving of alcohol daily and 6% higher for men consuming up to 3 
serving daily, when comparing to nondrinkers (Watters et al. 2010). However, an 
association between advanced prostate cancer and alcohol consumption was not 
observed. On the contrary, in another study within New Zealand cohort, alcohol 
consumption was associated with a reduced risk of prostate cancer (Karunasinghe et al. 
2013). Meta-analysis of 50 case-control and 22 cohort studies, in turn, provided no 
evidence of association between alcohol consumption and prostate cancer risk (Rota et 
al. 2012).  
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Recently, high coffee consumption was observed to reduce the risk of advanced prostate 
cancer (Wilson et al. 2011). However, according to another cohort study, there is no 
association between coffee consumption and overall prostate cancer risk (Shafique et al. 
2012). The association of α-linolenic acid, which is the most common omega-3 fatty 
acid in the Western diet, and prostate cancer risk has also been explored in many 
studies, but so far the results have been conflicting (Koralek et al. 2006, De Stefani et 
al. 2000, Brouwer, Katan & Zock 2004, Simon, Chen & Bent 2009). These studies have 
mainly explored the association of dietary α-linolenic acid consumption to prostate 
cancer. According a recent study, prostatic α-linolenic acid, independent of the amount 
of α-linolenic acid consumed, is associated with prostate cancer (Azrad et al. 2012). 
This could explain the conflicting results of the previous studies. 
In addition to multiple other health problems, obesity is known to increase the risk of 
prostate cancer. Although obesity seems to even decrease risk of non-advanced prostate 
cancer, it significantly increases the risk of advanced prostate cancer and prostate cancer 
specific mortality (Rodriguez et al. 2001b, Rodriguez et al. 2001a, Engeland, Tretli & 
Bjorge 2003, Wright et al. 2007, Andersson et al. 1997, Rodriguez et al. 2007). Obesity 
also increases the risk of prostate cancer progression to a castration resistant prostate 
cancer after androgen deprivation therapy (Keto et al. 2012). The reason for the 
association of obesity and prostate cancer is not fully understood, but it is known that 
obesity affects sex hormone levels (Keto et al. 2012). In addition to body weight, also 
height has been found to be associated with prostate cancer risk. Studies carried out 
among Norwegian, Japanese and North-American populations have pointed out that 
height is a significant prostate cancer risk factor; taller men have higher prostate cancer 
incidence and mortality than shorter men (Rodriguez et al. 2001a, Engeland, Tretli & 
Bjorge 2003, Minami et al. 2008). The association between height and higher prostate 
cancer risk could be explained by differences in the level of insulin-like growth factor. 
Tall men have higher levels of insulin-like growth factor, and increased level of this 
growth factor has been shown to be associated with prostate cancer (Chan et al. 1998, 
Stattin et al. 2000, Gunnell et al. 2001). 
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2.3 Prostate cancer genetics 
Prostate cancer is clinically a highly heterogenic disease. There can be many tumor foci 
in the same prostate gland, and these foci can represent different histological degrees. 
Also tumors representing same histological degrees may lead to different clinical 
outcomes. Genetic heterogeneity can explain this heterogeneity, at least to some extent. 
In turn, genetic heterogeneity results from genomic instability. (Boyd, Mao & Lu 2012) 
Despite the heterogenic nature of prostate cancer, recent studies suggest that on contrary 
to what was previously thought, the majority of multifocal prostate cancers may have 
monoclonal origins (Boyd et al. 2012, Lindberg et al. 2013). 
Heredity plays an important role also in prostate cancer. It has been estimated that 
autosomal dominant inheritance causes 5 – 10% of all prostate cancer cases, and a vast 
majority of early onset diseases (Bratt 2002, Lange et al. 2012). Germ-line mutations in 
high-penetrance susceptibility genes are characteristic in hereditary prostate cancer 
(Alberti 2010). For instance, RNASEL, ELAC2 and MSR1 are genes frequently 
harboring mutations in hereditary prostate cancer. Furthermore, somatic mutations in 
these genes are associated with sporadic prostate cancer (Noonan-Wheeler et al. 2006). 
On the contrary to the small number of known high-penetrance prostate cancer 
susceptibility genes, there are a large number of low-penetrance susceptibility genes. 
The interaction of environmental factors and alterations in multiple low-penetrance 
susceptibility genes plays a major role in the vast majority of prostate cancer cases. 
Moreover, a positive family history is the most important risk factor also in the case of 
non-hereditary prostate cancer. (Boyd, Mao & Lu 2012)  
As new technologies, such as comparative genomic hybridization (CGH) and next-
generation sequencing (NGS), are developed and evolve, knowledge about the genetic 
and genomic alterations in cancer is enormously increased. Along this, it becomes more 
and more clear that the genetic basis of prostate cancer is complex and diverse. Any 
single alteration is not enough to cause prostate cancer. It is commonly believed that 
cancer results from the accumulation of a large number of mutations in the same cell, 
also known as somatic evolution. Mutations are often classified to the driver and 
passenger mutations. Driver mutations are alterations that confer a selective growth 
advantage to the cell, thus driving it toward the development of cancer. On the contrary, 
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passenger mutations have no impact on the growth of the cell, but they occur in a cell 
subsequently or coincidentally with driver mutations. According to some studies, 
human solid tumors typically contain 40-100 coding gene alterations, including 5-15 
driver mutations. (Bozic et al. 2010) In addition, along the development and progression 
of cancer, genetic instability of the cells increases, meaning that they accumulate 
genetic changes at an abnormally rapid rate (Alberts et al. 2008). 
2.3.1 Chromosomal gains and deletions 
In comparison with other cancers, prostate cancer harbors relatively few protein-altering 
point mutations. Instead, chromosomal gains and deletions and gene fusions are more 
common, and multiple copy-number alterations are known to occur in prostate cancer 
(Barbieri, Demichelis & Rubin 2012)(Cheng et al. 2012). Frequent losses have been 
identified in at least the chromosomes 2q, 5q, 6q, 8p, 10q, 13q, 16q, 18q and 21q. Gains 
have been identified in the chromosomes 3q, 7q, 8q, 9p, 17q and Xq.  
Alterations in the chromosome 8 are among the most common alterations in prostate 
cancer. The association of 8q gain and 8p deletion with prostate cancer progression has 
been known for nearly two decades (Matsuyama et al. 1994, Van Den Berg et al. 1995). 
Along the development of new methods, it has been possible to map at least three 
independent 8q regions that are recurrently amplified in prostate cancer (Saramaki et al. 
2006). The prevalence of these amplifications increases among the progression of 
prostate cancer; in one study 8q gain was found from 5% of local prostate cancers, but 
from nearly 60% of hormone refractory prostate cancers. The same is applies also for 8p 
deletion (El Gammal et al. 2010). There are probably multiple genes affecting cancer 
progression in chromosome 8. Notable genes of this chromosome include the 
well-known oncogene MYC which locates on 8q24 and known prostate tumor 
suppressor NKX3.1 locating on 8p21 (Boyd, Mao & Lu 2012). 
Another remarkable chromosomal alteration in prostate cancer is the gain of 
chromosome Xq. The gene encoding androgene receptor (AR) locates on Xq12, and this 
locus has been found to be amplified in about 30% of CRPC cases, but nearly never in 
the early stages of cancer (Visakorpi et al. 1995). This amplification leads to AR 
overexpression, which can sensitize prostate cancer cells to androgen and makes 
androgen deprivation therapy inefficient (Waltering et al. 2009). 
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Deletion of 10q is yet another remarkable alteration in prostate cancer, since a 
commonly known tumor suppressor, phosphatase and tensin homolog (PTEN) gene 
locates on 10q23. Deletion of 10q is found from around 10% of prostate cancers (Sun et 
al. 2007). The loss of PTEN in prostate cancer correlates with an advanced stage of 
cancer and poor prognosis (McMenamin et al. 1999). In addition to prostate cancer, 10q 
deletion is also commonly found in bladder and breast cancers and in gliomas (Cairns et 
al. 1998, Li et al. 1997). In addition, PTEN point-mutations have been found from some 
inherited cancers and diseases (Lynch et al. 1997). 
17q gain is one of the most common copy-number alterations in prostate cancer and it is 
found from about 65% of primary prostate cancers (Bermudo et al. 2010). Similar 
amplification is common also in some other cancers, such as neuroblastoma and breast 
cancer (Bown et al. 2001, Barlund et al. 2002). MAFG, which belongs to the family of 
MAF proto-oncogenes and BCAS3, which is suggested to have a role in breast cancer 
development, locate in the 17q gain region (Kannan, Solovieva & Blank 2012, Gururaj 
et al. 2006). 
Similarly to prostate cancer, 13q deletion is a common alteration in many other cancer, 
such as leukemia, lung cancer, head and neck cancer and esophageal cancer (Zhou, 
Munger 2010). 13q contains several tumor suppressor genes, like ARL11, RGC32, 
RFP2 and CllD7 (Zhou, Munger 2010). On chromosome 3q, several areas have been 
found to be amplified often in prostate cancer (Sattler et al. 2000, Strohmeyer et al. 
2004). These loci contain many potential oncogenes, such as TLOC1/SEC62 (Jung et al. 
2006), GMPS, MLF1, SKIL, CCNL1 and ECT2 (Sun et al. 2007). 
2.3.1.1 9p13.3 gain 
9p13.3 gain is a recently found recurrent gain in prostate cancer. Saramäki et al. 
screened 13 xenografts and 5 prostate cancer cell lines by using array comparative 
genomic hybridization (aCGH) method. As a result, they identified a novel 
chromosomal gain at 9p13-q21 (Saramaki et al. 2006). The minimal region of the gain 
was mapped to 9p13.3. 9p13-q21 gain had been previously detected in DU145 cell line 
by cCGH, but proper analysis of this region had been lacking, as regions close to 
centromeres cannot be reliably analyzed by cCGH (Nupponen et al. 1998). Also Taylor 
et al. detected 9p13.3 gain from multiple prostatectomy samples (Taylor et al. 2010). In 
21 
 
yet another study, 9p13-q21gain was found from one prostate cancer metastasis sample 
and 9p12-13 from another sample by using aCGH method (Paris et al. 2003).  
In later studies, a high-level amplification of 9p13.3 was found to occur at 10% of 
prostatectomy specimens, while a low-level amplification was found from 32% of the 
samples. In addition, this amplification was associated with a higher PSA-level and 
poor progression-free survival in prostatectomy-treated patients (Leinonen 2007). In the 
same study, association between copy numbers and expression levels of the genes 
locating in 9p13.3 was studied by using RT-qPCR and FISH methods. According this 
study, promising candidate target genes for the 9p13.3 gain were PIGO, UNC13B, 
CD72, VCP, GALT, DCTN3, C9orf25, UBAP2, RUSC2 and UBE2R2 (Leinonen 2007). 
Moreover, also Taylor et al. analyzed gene expression levels and copy numbers within 
the 9p13.3 gain, and they found out that the expression of UBAP1, UBAP2, UBE2R2 
and WDR40A correlated with the gains in copy-numbers (Taylor et al. 2010). 
2.3.2 Gene fusions 
In general, there are two different gene fusion mechanisms that both can lead to 
tumorigenic alterations. Chromosomal rearrangements can promote the formation of 
chimeric fusion genes, which results in the expression of fusion proteins with altered 
activities. On the other hand, a gene can end up under the control of a different 
promoter, which leads to its altered expression (Boyd, Mao & Lu 2012). Previously, 
chromosomal rearrangements and gene fusions were thought to be common mainly in 
haematological malignancies and sarcomas (Kumar-Sinha, Tomlins & Chinnaiyan 
2008). However, technical limitations have hindered searching and studying gene 
fusions from solid malignancies. Recent advances in genomic profiling and 
bioinformatics, for example, have revealed gene fusions also from other cancers, 
including prostate cancer (Boyd, Mao & Lu 2012).  
The most common gene fusion in prostate cancer is TMPRSS2-ERG fusion. This fusion, 
found by Tomlins et al. in 2005, is found roughly from half of all prostate cancers 
(Boyd, Mao & Lu 2012, Tomlins et al. 2005). The fusion of ERG, a member of the ETS 
transcription factor family, with the promoter region of androgen-regulated TMPRSS2 
gene leads to the formation of an androgen-responsive oncogene (Rubin, Maher & 
Chinnaiyan 2011). The mechanism of this fusion is usually internal deletion or 
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chromosomal translocation. The results of studies focusing on the association between 
the presence of TMPRSS2-ERG fusion gene and the clinical outcome of prostate cancer 
have been slightly conflicting, but the fusion is possibly associated with poor clinical 
outcome (Boyd, Mao & Lu 2012). 
Instead of ERG, TMPRSS2 is sometimes fused with the other members of the ETS 
family, like ETV1, ETV4, ETV5 or ELK4 (Tomlins et al. 2005, Rubin, Maher & 
Chinnaiyan 2011). Also gene fusions of ETS transcription factors with 5’-fusion 
partners other than TMPRSS2, such as SLC45A3, NDRG1, HERPUD1 and FKBP5 have 
been reported (Boyd, Mao & Lu 2012). However, they are much more infrequent events 
than the TMPRSS2-ERG fusion and their significance for the progression and clinical 
outcome of prostate cancer is unclear. 
2.3.3 Epigenetics 
Epigenetic changes do not permanently alter the DNA sequence of genes. Instead, they 
induce conformational changes in the DNA double helix, thus affecting the access of 
transcriptional factors to promoter regions or to other regulatory sequences. Epigenetic 
changes can be preserved from cell to cell and they can also be heritable. (Albany et al. 
2011) Epigenetic regulation is very important for the development of eukaryotic 
organisms, but it also plays a role in many human diseases and dysfunctions. 
Like in many other cancers, epigenetic changes have a role also in prostate cancer. DNA 
methylation and histone modifications are the two best understood epigenetic 
mechanisms and they both are known to affect prostate cancer growth and metastasis. 
Hypermethylation of CpG rich areas in the promoter regions of several genes occurs 
frequently in prostate cancer (Paone, Galli & Fabbri 2011). This results in 
transcriptional silencing of the genes under the control of the hypermethylated promoter 
regions. The promoter regions of many tumor suppressor genes are known to be 
frequently hypermethlylated in prostate cancer, and silencing of these genes promotes a 
carcinogenetic effect (Paone, Galli & Fabbri 2011). Genes frequently hypermethylated 
in prostate cancer include for example GSTP1, APC and RAFFS1a (Jeronimo et al. 
2011). On the contrary to hypermethylation, hypomethylation of promoter regions leads 
to increased expression of the genes regulated by these promoters. When compared to 
hypermethylation, promoter hypomethylation is far more infrequent in prostate cancer, 
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although it is known to be an important mechanism in some other cancers (Jeronimo et 
al. 2011). However, some genes, including LINE1, IGF2, PLAU and CYP1B1, have 
been reported to be hypomethylated also in prostate cancer (Jeronimo et al. 2011). 
MicroRNAs (miRNAs) are small non-coding RNAs that have complex regulatory 
functions in cells. miRNAs act mainly by binding to the 3’-untranslated region of their 
target mRNA thus silencing them. However, they can also promote translation by 
binding to the 5’-untranslated region of their target transcripts (Paone, Galli & Fabbri 
2011). It is also known that miRNAs can affect the epigenetinc control of genes. In 
cancer cells, this can lead to reduced methylation and re-expression of previously 
epigenetically silenced tumor suppressor genes (Paone, Galli & Fabbri 2011). In 
addition, genes coding miRNAs can undergo the same epigenetic regulatory mechanism 
discussed above, and hence, they can be silenced similarly to protein coding genes 
(Jeronimo et al. 2011). The interplay of miRNA induced translational silencing and 
epigenetic mechanisms creates a complex network of regulatory events, which is not yet 
fully understood. However, this miRNA-epigenetics network seems to have a 
significant role in many disorders, including prostate cancer. 
2.3.4 Oncogenes 
Genes, in which a gain-of-function mutation can contribute to cancer, are called 
proto-oncogenes (Alberts et al. 2008). Proto-oncogenes can become active oncogenes 
either through point-mutations, amplifications or rearrangements (Alberts et al. 2008). 
Many oncogenes have a fundamental impact on signaling pathways and they are critical 
in various types of cancer, while some oncogenes are specifically active in only certain 
types of cancers (Alberts et al. 2008). 
MYC is a regulatory gene that encodes transcription factor MYC, which is thought to 
regulate 15 % of all human genes (Dasgupta, Srinidhi & Vishwanatha 2012). MYC is 
involved in the regulation of cellular proliferation, differentiation and apoptosis, 
(Grandori et al. 2000). MYC is also known to act as an oncogene in various cancers, 
frequently through genomic amplification (Dang 2012). As previously mentioned, MYC 
is located in the chromosomal region 8q24, which is recurrently amplified in prostate 
cancer (Boyd, Mao & Lu 2012). 
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In contrast to MYC, AR, which encodes androgen receptor, can be seen as a cancer-
specific proto-oncogene. Androgen receptor is a nuclear receptor that has many 
functions in human development and physiology. On the other hand, androgen receptor 
is also involved in all stages of prostate tumorigenesis (Li, Al-Azzawi 2009). AR often 
transforms to oncogene during prostate cancer progression (Visakorpi et al. 1995, Han 
et al. 2005). This most commonly happens through gene amplifications, while gain-of-
function mutations in AR are very rare (Visakorpi et al. 1995, Hay, McEwan 2012). 
Interestingly, androgen receptor may occasionally have an oncogenic role also in breast 
cancer. (Hickey et al. 2012).  
ERBB2 is a gene that encodes HER2, which is a member of the epidermal growth factor 
receptor family. ERBB2 is located in the chromosomal region 17q12, which is often 
amplified in prostate cancer, as well as in breast cancer and in some other malignancies. 
In cells, HER2 receptor acts by inducing the activation of the PI3K/Akt signaling 
pathway. Uncontrolled activation of this central signaling pathway leads to tumorigenic 
events in cells (Le Page et al. 2012). The overexpression of ERBB2 has a high clinical 
relevance in the treatment of breast cancer, as cancers overexpressing it can be treated 
by monoclonal antibodies against HER2 (Carter et al. 1992). In the case of prostate 
cancer, however, the expression of ERBB2 is relatively low it is not a relevant target for 
cancer treatments (Savinainen et al. 2002). 
2.3.5 Tumor suppressor genes 
In contrast to oncogenes, tumor suppressor genes are genes in which a loss-of-function 
mutation can drive a cell towards the development of cancer (Alberts et al. 2008). 
Tumor suppressor genes can be inactivated in many ways, for example by chromosomal 
deletions, point mutations or by epigenetic mechanisms. Unlike with oncogenes, usually 
both alleles of a tumor suppressor gene have to be altered for cancer to develop (Alberts 
et al. 2008). Typically tumor suppressor genes regulate either the detection and repair of 
DNA damage, protein ubiquitination and degradation or cell cycle checkpoint responses 
(Sherr 2004). 
Loss-of-function mutations in TP53, the gene coding p53 protein, are common in 
prostate cancer, as well in many other cancers (Isaacs, Kainu 2001). p53 is activated by 
phosphorylation in response to cellular stress such as DNA damage, and when activated 
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it acts as a transcription factor. The activation of the p53 pathway can result in cell cycle 
arrest, cell senescence and apoptosis. (Levine 2011) A recent study demonstrated that 
docetaxel, a drug that is commonly used as the first line treatment for castration 
resistant prostate cancer, induces the phosphorylation of p53. In accordance with this 
finding, the mutational status of p53 is determinant of docetaxel sensitivity of prostate 
cancer cells (Liu et al. 2013). 
PTEN is yet another well-known tumor suppressor gene. It is commonly inactivated in 
many different types of cancer, such as glioma, melanoma and carcinoma of the 
endometrium, kidney, breast, lung, upper respiratory track and prostate cancers (Li et al. 
1997, Pourmand et al. 2007). PTEN, located on 10q23, encodes a dual-specificity 
phosphatase and is known to act as a part of the PI3K-PTEN-AKT signaling pathway. 
This pathway is important in the regulation of multiple essential cellular processes like 
apoptosis, cell metabolism, cell proliferation and cell growth (Pourmand et al. 2007, de 
Muga et al. 2010). Inactivation of PTEN and the subsequent activation of the AKT 
pathway is a frequent event in prostate cancer progression, and the lack of PTEN 
expression is known to correlate with advanced pathological state and with a high 
Gleason score (de Muga et al. 2010). The frequency of PTEN mutations in metastatic 
prostate cancer varies among the different studies, but usually it is reported to be 
between 20 and 60 % (Pourmand et al. 2007, de Muga et al. 2010). 
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3. AIMS OF THE RESEARCH 
The goal of this Master’s thesis study was to clarify the role of UBAP2 in prostate 
cancer. Previous studies have suggested that UBAP2 might be a potential oncogene and 
a target gene of chromosomal gain in 9p13.3. The main aims of the study were:   
1) Cloning UBAP2 gene. 
2) Analyzing the effects of overexpression of UBAP2 in prostate cancer cells.  
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4. MATERIAL AND METHODS 
4.1 Cloning of UBAP2 
The starting material for the cloning of UBAP2 was commercial Human Universal 
Reference RNA (Agilent) and RNA previously extracted from PC-3, DU145 and 22Rv1 
cell lines. cDNA was synthesized from extracted RNA by using SuperScript III reverse 
transcriptase (Invitrogen) together with oligo(dT) primers (Invitrogen). The cDNA was 
used as the template for PCR amplification of the UBAP2 gene. The primers used in 
this PCR are shown in the table 1., and they are complementary to the first and the last 
exons of UBAP2. The PCR was performed using Phusion
TM
 High-Fidelity DNA 
Polymerase (Finnzymes) under the default conditions recommended by the 
manufacturer. PCR products were purified in 1% agarose and visualized by ethidium 
bromide. The amplified DNA was extracted from the agarose gel by using QIAquick 
Gel Extraction Kit (Qiagen). As Phusion
TM
 High-Fidelity DNA Polymerase generates 
blunt-ended products, 3’ A-overhangs were added to the purified PCR products by 
using Dynazyme
TM
 II DNA Polymerase (Finnzymes) and adenosine nucleotides. The 
reaction was incubated with the recommended buffer at 72 °C for 20 minutes. 
The cloning of UBAP2 was performed by using TOPO-TA based TOPO-XL cloning kit 
(Invitrogen) and pCR-XL-TOPO® vector (Invitrogen). The constructs were then 
transformed into One Shot® chemically competent TOP10 E. coli cells (Invitrogen) 
using heat-shock transformation. Cells were cultured overnight on LB plates containing 
50 µg/ml of kanamycin. Transformation was performed according to manufacturer’s 
instructions. To ensure successful cloning, colony PCR was performed on multiple 
colonies with UBAP2 specific primers. Primers used for the colony PCR were same as 
used for RT-qPCR. The sequences of these primers are shown in the table 1. The 
products of the colony PCR products were loaded onto 1% agarose gel and visualized 
by ethidium bromide. Positive colonies were cultured overnight in small volumes of LB 
medium containing 50 µg/ml of kanamycin. Plasmid DNA was extracted by using 
GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich).   
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4.2. DNA sequencing 
Plasmid DNA was sequenced by Sanger’s method using BigDye Terminator v3.1 Cycle 
Sequencing kit (Applied Biosystems) and ABI-3130xl genetic analyzer (Applied 
Biosystems). DNA was amplified prior to sequencing using Bio-Rad C1000
TM
 Thermal 
Cycler (Bio-Rad). Each sequencing reaction included 100-300 ng of DNA, 6 pmol of 
primers, 1,5 µl of 5x sequencing buffer and 1,0 µl of BigDye Terminator reaction mix 
(Applied Biosystems). The volume of the sequencing reactions were adjusted to 10 µl 
using sterile, deionized water. Primers used for the sequencing PCR are shown in the 
table 1. The sequencing reactions were denatured at 96 °C for 1 minute, followed by 30 
cycles of 10 s at 96 °C, 10 s at 50 °C and 4 min at 60 °C. Amplified DNA was 
precipitated by adding 25 µl of 96% ethanol and 1 µl of 3 M sodium acetate (pH 5.2) 
and incubating the reactions for 15 minutes at room temperature. Precipitated DNA was 
pelleted by centrifugation at 2000 g for 45 minutes, and supernatants were discarded. 
The DNA pellets were washed with 125 µl of 70% ethanol and pelleted again by 
centrifugation at 2000 g for 15 minutes. Supernatants were discarded, the DNA pellets 
were air-dried at room temperature and resuspended into 12,5 µl of Hi-Di
TM
 formamide 
(Applied Biosystems). Resuspended DNA was denatured by incubating the samples at 
95 °C for 3 minutes, followed by cooling on ice. Sequencing was performed by using 
ABI 3130xl genetic analyzer (Applied Biosystems). Sequences were analyzed with 
Chromas Lite 2.1 software (Technelysium). 
4.3. Subcloning to expression vector 
The UBAP2 inserts confirmed by sequencing were subcloned into the pCMV-SPORT6 
expression plasmid by using MluI and NotI restriction enzymes. Restriction enzymes, 
T4-DNA ligase and the used buffers were purchased from New England Biolabs. 
Restriction reactions were performed by double digestion in 1x NEBuffer 3 at 37 °C for 
30 minutes. After restriction, UBAP2 inserts and linearized pCR-XL-TOPO® plasmids 
were separated on 1% agarose gel. The UBAP2 inserts were purified using QIAquick 
Gel Extraction Kit (Qiagen). Linearized pCMV-SPORT6 plasmid was purified using 
QIAquick PCR Purification Kit (Qiagen). The ligation reactions of linearized 
pCMV-SPORT6 plasmid and UBAP2 inserts were performed at room temperature for 
10 minutes. Constructs were transformed into One Shot® chemically competent TOP10 
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e. coli cells. Transformed cells were then cultured overnight on LB plates containing 
50 µg/ml of ampicillin. Colony PCR was performed on multiple colonies with UBAP2 
specific primers as described above. Positive colonies were cultured overnight in small 
volumes of LB medium containing 50 µg/ml of ampicillin. Plasmid DNA was extracted 
by using GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich). DNA was sequenced as 
previously described. The constructs that were selected for overexpression experiments 
were cultured overnight in larger volumes of LB medium containing 50 µg/ml of 
ampicillin. After an overnight incubation at 37 °C, plasmid DNA was extracted by using 
Qiagen Maxiprep kit (Qiagen). 
4.4 Cell lines 
Both prostate cancer cell lines used in this study, PC-3 and LNCaP, were obtained from 
American Type Culture Collection (ATCC). The cells were cultured at 37 °C and 5% 
CO2. Cell cultures were subcultured every three to four days. The basal media used 
were Ham’s F12 with 10% fetal bovine serum and 2 mM L-glutamine for PC-3 cell line 
and RPMI 1640 with 10% fetal bovine serum and 2 mM L-glutamine for LNCaP cell 
line. Basal media and fetal bovine serum were purchased from Lonza. 
4.5 Transient transfection  
Transfection of prostate cancer cells with UBAP2 constructs were performed using 
jetPEI® transfection reagent (Polyplus-transfection). 15 000, 20 000 or 30 000 cells were 
seeded on 24-well plate and incubated 24h before transfection. Transfections were 
performed according to manufacturer’s instructions, using 500 ng of DNA per 1 cm2 
area. Equal mass amounts of different UBAP2 constructs were transfected to cells, and 
control cells were transfected with expression vectors lacking the UBAP2 insert. 
4.6 Proliferation assay 
Cells were quantified by using AlamarBlue assay (Invitrogen) and light microscopy 
one, three and five days after transfection. Six parallel samples were used in each 
experiment. For AlamarBlue assay, 50 µl of AlamarBlue reagent was added to 1 ml of 
medium and 100 µl of medium was collected 90 minutes after adding the AlamarBlue. 
Absorbances of collected samples were then measured spectrophotometrically at 
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570 nm using the 2104 EnVision® Multilabel Reader (PerkinElmer). In this assay, 
increase or decrease in the metabolic activity of cell culture is measured by assaying the 
relative absorbances of the samples. In turn, the overall metabolic activity of the cell 
culture generally correlates with the number of cells in the culture. The number of cells 
was also quantified by imaging them using Olympus IX71 inverted light microscope 
(Olympus) and Surveyor software (Objective Imaging). Images were analyzed and cell 
surface areas were determined by using ImageJ software (National Institutes of Health). 
4.7 RNA extraction and RT-qPCR 
Total RNA was extracted from transfected cells using TRI Reagent® (Sigma). RNA 
extraction was performed according to manufacturer’s instructions. For extraction, 
200 000 cells were seeded on 6-well plate and transfected with UBAP2 or control 
constructs one day prior to RNA extraction as previously described. 
For real time quantitative PCR (RT-qPCR), RNA was reverse transcribed with 
SuperScript III reverse transcriptase (Invitrogen) by using oligo(dT) primers 
(Invitrogen). Standard curves were prepared from RNA extracted from non-transfected 
PC-3 cells by using 5-fold dilution series. All expression values were normalized to 
housekeeping gene TBP (TATA binding protein) and sterile water was used as negative 
control. RT-qPCRs were carried out in Bio-Rad CFX96™ Real-Time PCR Detection 
System (Bio-Rad) with Maxima
TM
 SYBR Green/ROX qPCR Master Mix (Fermentas). 
Manufacturer’s instructions were followed, and reaction conditions were optimized for 
each primer pair. The primers used are summarized in the table 1. Following the PCR, 
amplified PCR products were analyzed by electrophoresis on 1% agarose gel to ensure 
correct amplification. PCR results were analyzed using CFX Manager Software. 
4.8 Immunocytochemistry 
For immunocytochemistry, 200 000 cells were seeded on a 6-well plate on the top of 
cover glass and transfected with UBAP2 or control constructs as described above. Three 
days after the transfection cover glasses were removed and the cells were fixed with 4% 
paraformaldehyde. Cells were permeabilized using 0,5% NP-40/PBS solution. The 
fixed cells were probed with rabbit-anti-UBAP2 primary antibody and fluorescent-
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labeled Alexa Fluor 594 goat-anti-rabbit secondary antibody. The cover glasses were 
mounted on object slides using Vectashield mounting media (Vector Labs) containing 
DAPI. Slides were imaged using Zeiss Axio Imager M2 fluorescence microscope. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Primer sequences. The left-hand panels shows primer name and its binding position, 
and the right-hand panel shows primer sequence. 
  
CLONING PRIMERS 
Gene / exon Primer sequence 5'-3' 
Forward 
UBAP2 / exon 1 GAGAGCAGCAGCGATTTTCT  
Reverse 
UBAP2 / exon 29 TACCCAAACAGCCTTGAACC 
  SEQUENCING PRIMERS 
Gene / exon Primer sequence 5'-3' 
Forward 
M13 Forward (-20) GTAAAACGACGGCCAG 
UBAP2 / exon 1 GAGAGCAGCAGCGATTTTCT  
UBAP2 / exon 5 ATTCAGAAAACAAAGAGAAT 
UBAP2 / exon 6 TGCAATCAAGTGGACAAACC 
UBAP2 / exon 9-10 GTTCTTATGGACTCAAAGGG 
UBAP2/ exon 12 CAACAATCAGATGGCACCAG 
UBAP2 / exon 16 TGTCTTCCTCTTATGACCAG 
UBAP2 / exon 20 CGGCAGCGACCTCCGTCTCA 
UBAP2 / exon 24 ACTCTGCATCCCCTGCACCC 
UBAP2 / exon 27 TATCAGTGTCTTCAAGCACC 
UBAP2 / exon 28 TTTGACAAGCAGGGATTTCA 
Reverse 
M13 Reverse CAGGAAACAGCTATGAC 
UBAP2 / exon 13 GTGGTGCAAGCTCTCCAAAT 
UBAP2 / exon 16 TGGTTCCTGGAGCTGACTCT 
UBAP2 / exon 28 GCTGGCAAGATGTGTAGGAA 
UBAP2 / exon 29 TACCCAAACAGCCTTGAACC 
  RT-QPCR PRIMERS 
Gene / exon Primer sequence 5'-3' 
Forward 
TBP3 GGGGAGCTGTGATGTGAAGT 
UBAP2 / exon 1 GAGAGCAGCAGCGATTTTCT  
UBAP2 / exon 16 TGTCTTCCTCTTATGACCAG 
UBAP2 / exon 17 TGGTCGAAGTCAGCAGACAC 
Reverse 
TBP3 GAGCCATTACGTCGTCTTCC 
UBAP2/ exon 3 ACGCATCTGTTCAGCTGTTG 
UBAP2 / exon 16 TGGTTCCTGGAGCTGACTCT 
UBAP2 / exon 18 GCTGAGAGAGAGGGCTGCTA 
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5. RESULTS 
5.1 Cloning of Full Length UBAP2 and different UBAP2 splice variants 
In this study, the full-length cDNA of human UBAP2 was successfully cloned. In 
addition, the cloning yielded multiple different UBAP2 splice variants. The structures of 
fully sequenced variants are presented in the Figure 2. One of these splice variants, 
E1-6/9-29, contains all but two exons and it is probably translated to a slightly truncated 
UBAP2 protein. Similarly, the translation of the E29’/’14-29 variant probably results in 
N-terminally truncated UBAP2 protein. The rest of the variants produce C-terminally 
truncated proteins caused by premature stop-codons or alternative splicing. In some 
variants the splice site or sites differ from the typical 3’ and 5’ splice sites. Besides of 
the variants presented here, cloning yielded a dozen of different variants that we did not 
sequence completely. 
5.2 Verification of UBAP2 overexpression by RT-qPCR 
We subcloned the full length UBAP2 and three truncated variants, E1-6/9-29, E1-4’/’29 
and E29’/’14-29 to pCMV-Sport6 expression vector and overexpressed them in prostate 
cancer cells. The overexpression of UBAP2 in transfected prostate cancer cells was 
verified by RT-qPCR. The results of the RT-qPCR experiments are presented in the 
Figure 3A. These results show that both PC-3 and LNCaP cells transfected with full-
length UBAP2 express UBAP2 mRNA at high levels as compared with cells transfected 
with empty expression vector. The overexpression of UBAP2 in cells transfected with 
truncated UBAP2 variants was verified by using RT-qPCR with two different gene-
specific primer pairs, each having priming sites in different parts of the mRNA 
molecule. Figure 3B-C shows that the cells transfected with variants E1-6/9-29 and  
E1-4’/’29 overexpress UBAP2 exons 1-3 at low and high levels, respectively, when 
compared to the cells transfected with the E29’/’14-29 variant or empty expression 
vector. Correspondingly, the cells transfected with variants E1-6/9-29 and E29’/’14-29 
overexpress UBAP2 exon 16, unlike the cells transfected with the E1-4’/’29 variant or 
empty expression vector. Again, the expression level of UBAP2 in the cells transfected 
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with variant E1-6/9-29 is lower than the expression level in the cells transfected with 
variant E29’/’14-29. 
5.3 The effects of UBAP2 expression on the growth of prostate cancer 
cells 
The effects of UBAP2 expression on cell growth were studied by using two different 
prostate cancer cell lines, PC-3 and LNCaP. Figure 4. shows the results of the cell 
growth experiments conducted by using PC-3 cells transfected with full length UBAP2 
(Figure 4A) or with truncated UBAP2 variants (Figure 4B). In the case of the full length 
UBAP2, it seemed that the over expression of UBAP2 slightly improved cell growth, but 
the difference was not statistically significant (p > 0.05). In the case of the truncated 
UBAP2 variants, all studied variants seemed to significantly (p < 0.05) inhibit cell 
growth. Figure 5. shows the results of the cell growth experiment performed by using 
LNCaP cells transfected with full length UBAP2 (Figure 5A) or with truncated UBAP2 
variants (Figure 5B). In case of the full length UBAP2, the effect is similar as with PC-3 
cells and UBAP2 seems to slightly improve cell growth when compared to the control 
cells. However, the difference in the growth rates of the cells was not statistically 
significant (p < 0.05). In the case of the truncated UBAP2 variants, all variants seemed 
to slightly inhibit cell growth, but the difference was not statistically significant  
(p < 0.05). 
5.4 Verification of UBAP2 overexpression at the protein level, and its 
localization by fluorescence immunocytochemistry 
Fluorescence immunocytochemistry was applied to analyze UBAP2 protein expression 
and localization in prostate cancer cells transfected with full-length UBAP2. We 
observed that around 20% of the cell population overexpressed UBAP2 at the protein 
level. With LNCaP cells this fraction was slightly higher as compared with PC-3 cells. 
As expected, cells transfected with an empty expression vector did not overexpress 
UBAP2. We also observed that the localization of UBAP2 was strongly cytoplasmic. 
Representative fluorescence microscope images of PC-3 and LNCaP cells transfected 
with UBAP2 are shown in the Figure 6.   
34 
 
 Figure 2. The exon structures of the cloned UBAP2 variants. The uppermost bar represents full-length UBAP2 cDNA and the lower bars represent truncated 
UBAP2 variants. A darker shade of blue represents sequences that are in frame, a lighter shade of blue represents sequences out of frame. Stripes represent 
frameshifts. Red color represents rearranged exon order. Apostrophe (‘) represents non-canonical exon boundaries. 
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Figure 3. Relative mRNA expression levels for UBAP2. 
A) The expression of full-length UBAP2 mRNA in LNCaP and 
PC-3 cell lines transfected with UBAP2 or with an empty 
expression vector. Error bars represent standard deviations of 
two samples. B) and C) The relative expression levels of 
UBAP2 exon 16 and exons 1-3, respectively, in PC-3 cell lines 
transfected with truncated UBAP2 variants E1-6/9-29, 
E29’/’14-29 and E1-4’/’29. The cDNA regions amplified in 
RT-qPCR are indicated by the title of each figure.  
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Figure 4. The relative growth of PC-3 cells transfected with UBAP2 quantified by Alamar 
Blue assay. A) 20 000 PC-3 cells were seeded to 24-plate wells and transiently transfected to 
overexpress full length UBAP2 or with empty expression vector. Cell growth was analyzed on 
the first, third and fifth day after transfection. B) 15 000 PC-3 cells were seeded to 24-plate 
wells and transiently transfected to overexpress three different UBAP2 splice variants or with 
empty expression vector. Cell growth was analyzed on the first, third and fifth day after 
transfection. 
 
Figure 5. The relative growth of LNCaP cells transfected to express UBAP2 quantified by 
digital imaging. A) 30 000 LNCaP cells were seeded to 24-plate well and transiently 
transfected to overexpress full length UBAP2 or with empty expression vector. Cell growth was 
analyzed on the first, third and fifth day after transfection. B) 30 000 LNCaP cells were seeded 
to 24-plate well and transiently transfected to overexpress three different UBAP2 splice variants 
or with empty expression vector. Cell growth was analyzed on the first, third and fifth day after 
transfection. 
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Figure 6. Over expression of UBAP2 in PC-3 and LNCaP cells transfected with full-length 
UBAP2. The upper row represents PC-3 and the bottom row represents LNCaP cells. The 
left-hand-side panel shows anti-UBAP2 immunostaining, the center panel nuclear DAPI 
staining and the right-hand-side panel shows merged images. 
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6. DISCUSSION 
In this study, we cloned UBAP2 gene and overexpressed it in prostate cancer cells. 
Previous studies carried out by our group have pointed out that chromosomal region 
9p13.3 is recurrently amplified in prostate cancer. This amplification was also found to 
be associated with higher PSA-levels and poor progression-free survival in 
prostatectomy treated patients (Leinonen 2007). Chromosomal region 9p13.3 harbors 
multiple genes but none of them has known tumorigenic functions. For some of these 
genes, the level of the mRNA expression correlated with the copy number, thus making 
them candidate genes of that amplification (Leinonen 2007, Taylor et al. 2010). In the 
present study, we focused on one of these candidate genes locating in the 9p13.3 region, 
UBAP2, which encodes ubiquitin associated protein 2 (UBAP2). Function of this 
protein is unknown. UBAP2 contains one UBA-domain, which is known to bind mono- 
or polyubiquitin molecules. This domain is found from many proteins involving in 
ubiquitin-dependent signaling pathways. 
According to previous studies conducted with clinical samples, the expression of 
UBAP2 mRNA is significantly increased in prostate cancer compared to benign 
prostatic hyperplasia. In addition, down-regulation of UBAP2 by siRNA significantly 
decreases the proliferation rate of prostate and breast cancer cells (unpublished data of 
this group). RNA sequencing results also show that UBAP2 levels increase in castration 
resistant prostate cancer compared to prostate cancer (unpublished results).  These 
previous results indicate that UBAP2 is likely to be a notable factor in the regulation of 
proliferation of prostate cancer cells and supported the choice of UBAP2 as the subject 
of this study. 
In a previous study by Al-Balool et al., it was shown that UBAP2 mRNA is a common 
target for post-transcriptional exon shuffling (PTES) events (Al-Balool et al. 2011). 
PTES events, also known as exon scrambling, are rearrangements of mRNA molecules 
originating from a single gene. In PTES rearrangements the exon-intron boundaries 
remain intact but the order of exons in the transcript differs from the genomic order of 
exons. The frequency and functional significance of PTES transcripts is in many cases 
still largely unknown. RNA sequencing studies from clinical prostate samples, in turn, 
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indicate that some UBAP2 exons are expressed at different level in castration resistant 
prostate cancer as compared to benign prostatic hyperplasia (unpublished data of this 
group). For example, the exons from 4 to 7 are overexpressed in castration resistant 
prostate cancer. This might indicate that the splice variants containing these exons are 
more frequent in castration resistant prostate cancer than in benign prostatic hyperplasia.  
6.1 Cloning of full-length UBAP2 and splice variants 
In this study, we cloned for the first time a cDNA coding for the human UBAP2 gene. 
The cloning procedure of this gene was complicated by the huge number of UBAP2 
splice variants. When reverse transcribed RNA was amplified with UBAP2 specific 
PCR primers, every reaction yielded several products, differing by the size and by the 
exon structure. These included transcripts processed by exon skipping, alternatively 
spliced exon 5’ and 3’ splice sites and intron retention. In fact, cloning of the full-length 
UBAP2 cDNA proved to be quite challenging, as both PCR and TOPO-cloning seem to 
favor the truncated variants. It is possible that reason for this bias in the cloning reaction 
was technical, as shorter DNA strands are more easily amplified in PCR and somewhat 
easier to transform to cells. Nevertheless, it is also possible that RNA, which was our 
starting material for cloning, contain a greater amount of truncated UBAP2 variants than 
full-length UBAP2 mRNA. 
 In addition to the variants lacking exons in the middle of the structure, we cloned one 
transcript, E29’/’14-29, which was truncated from the 3’ end. In this variant, there was a 
short, incorrectly positioned stretch of sequence from the exon 29 containing the 
binding site for the reverse primer used in the amplification of reverse transcribed 
UBAP2 mRNA. This stretch of sequence is joined to the 3’ side of the exon 14 in 
inverted orientation and complementary to the sense strand.  It is not likely that this is 
due to nonspecific primer binding, as there is a short sequence from the exon 29 outside 
the primer binding site. Instead, it may have arisen from intragenic trans-splicing. In 
this alternative mode of splicing, two distinct pre-mRNA molecules encoding the same 
protein are joined together to form a single processed mRNA (Horiuchi, Aigaki 2006). 
This theory is supported also by the recent report describing that UBAP2 is a common 
target for post-transcriptional exon shuffling (PTES) events. However, in this case, both 
3’ and 5’ splice sites were non-canonical, which is atypical for PTES and trans-splicing 
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events. Moreover, sequence from the exon 29 was joined with 3’ end of exon the 14 is 
in antisense orientation. This raises doubts about the possibility of experimental 
artifacts. A closer look at the sequence of UBAP2 mRNA revealed, that there was a 
significant sequence similarity between the splice boundaries of both splice donor and 
acceptor (data not shown). This suggests that observed transcripts may have resulted 
from an experimental artifact caused by reverse transcriptase template switching during 
cDNA preparation (Houseley, Tollervey 2010). 
Template switching is a process, in which reverse transcriptase jumps to another 
location within the template without terminating DNA synthesis (Houseley, Tollervey 
2010, Cocquet et al. 2006). Template switching can also occur in vitro during cDNA 
synthesis. Reverse transcriptase template switching has been implicated in the untypical 
intramolecular splicing events that are sometimes wrongly interpreted as intramolecular 
trans-splicing processes. The key indicators of this process are non-canonical splice 
sites and high sequence identity between the donor and acceptor sites. Template 
switching can also result in trans-splicing between sense and antisense transcripts, as 
reverse transcriptase can jump from mRNA to the cDNA being produced by another 
enzyme from the same template (Houseley, Tollervey 2010). All of the considerations 
presented above support the hypothesis that the E29’/’14-29 transcript is a result of 
reverse transcriptase template switching event that has occurred in vitro during the 
cDNA synthesis.  
This observation lead us to question if some other UBAP2 variants are false transcripts 
as well. A more detailed look at the sequences pointed out that most of the variants 
having non-canonical splice sites also had high sequence identity between the donor and 
the acceptor sites. On the contrary, the splice sites of the variants with canonical exon 
boundaries had no notable sequence identity. This strongly indicates that template 
switching events have taken place in the reverse transcription of UBAP2 splice variants 
with non-canonical exon boundaries. On the other hand, the splice variants with 
canonical exon boundaries are likely to have resulted from regular cis-splicing in the 
cells. 
Reverse transcriptase template switching is a relatively rare event that causes artifacts 
mainly in high throughput experiments that produce a huge volume of transcriptome 
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data (Houseley, Tollervey 2010). However, some mRNAs, like FOXL2, are reported to 
be more prone to the template switching than others (Cocquet et al. 2006). The reason 
may be the mRNA secondary structure, which brings two separate homological regions 
close to each other. Also the high number of homological regions may increase the 
likelihood of the template switching. According to our results, UBAP2 seems to be 
prone to template switching. In the future studies, it would be reasonable to try to 
reduce template switching, as it seems to be a recurrent artifact in the cDNA synthesis 
of UBAP2. The use of different reverse transcriptases might help to avoid template 
switching, as Super Script and AMV reverse transcriptases have been shown to have the 
different template switching propensities (Houseley, Tollervey 2010). An increase in 
the reaction temperature has also been reported to inhibit template switching (Cocquet 
et al. 2006). Two UBAP2 false variants, E1-4’/’29 and E29’/’14-29, encode N- and C-
terminally truncated UBAP2 protein, respectively. 
The presence of different mRNA variants can be studied by northern blot analysis. In 
this method, total RNA extracted from cells or tissue sample is separated by agarose gel 
electrophoresis, blotted to a membrane and detected with a DNA probe labeled with 
radioactive phosphorus. Since the RNA molecules are separated according to their size 
within the agarose gel, one should be able to detect all variants with different sizes, as 
long as they contain the region recognized by the probe. If RNA ladder is used, also the 
size of the detected RNA molecules can be analyzed. Despite of its efficiency in 
detecting mRNA molecules, northern blot analysis is a complex method and the quality 
of starting material plays a major role in the success of analysis. In this study, we tried 
to detect different UBAP2 splice variants by using northern blotting, but the analysis of 
the results was prevented by the low intensity of the bands and by the high background 
signal (data not shown). The reason for these results could be technical, e.g. poor 
quality of RNA or poor probe design. It is also possible that the levels of UBAP2 
variants in the samples were very low and fell below the detection limit.  
6.2 Overexpressing UBAP2 in prostate cancer cells 
Our aim was to study whether the overexpression of UBAP2 has effects on the growth 
and proliferation of prostate cancer cells. To do this, we transfected cells with an 
expression plasmid carrying the UBAP2 gene. We also ensured the efficiency of the 
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transfection method before carrying out other experiments. We verified the 
overexpression of UBAP2 at the mRNA-level by RT-qPCR. In this method, RNAs 
extracted from cells are converted to complementary DNA, and the amount of DNA is 
quantified during PCR-amplification by utilizing fluorescent dyes binding to double 
stranded DNA. By using RT-qPCR, we were able to measure the amount of UBAP2 
mRNA in cells transfected with UBAP2 gene and compare it to that of the cells 
transfected with control vector. 
UBAP2 was overexpressed under cytomegalovirus (CMV) promoter, which typically 
induces a very strong expression. Therefore, artificial overexpression might be several-
fold higher than naturally occurring levels of expression. According to RT-qPCR 
results, cells transfected with either full-length or truncated UBAP2 variants overexpress 
it at mRNA-level, and the difference to the cells transfected with empty expression 
vector was significant. However, there were significant differences in the expression 
levels between different truncated variants. Variant E1-6/9-29 was overexpressed at a 
much lower level when compared to variants E1-4’/’29 and E29’/’14-29. The reasons 
for these differences in the expression levels are still largely unknown. Variant E1-6/9-
29 is significantly longer (4130 bp) than the other variants (E1-4’/’29 is 406 bp and 
E29’/’14-29 is 2901 bp). We transfected cells with equal mass amount of DNA, which 
result in higher molar amount of shorter DNA strand and in higher plasmid copy 
number in the cells. Anyhow, the difference caused by this is quite minor (about 2 fold) 
and should not cause large variations in the expression level of different splice variants. 
It is also possible that the transfection efficiency is higher for shorter DNA strands. In 
addition to variations in the rates of mRNA synthesis, there could be differences in the 
degradation rates of different mRNA molecules. Hence, it is possible that E1-6/9-29 
UBAP2 variant is degraded at a much higher rate than shorter truncated variants. These 
kind of differences in the turnover rates of different mRNA variants might be caused by 
the presence of different stabilizing and destabilizing elements within different mRNA 
molecules. 
The cell lines we used for the overexpression and proliferation studies were LNCaP and 
PC-3. Both of these cell lines are widely used human prostate adenocarcinoma cell 
lines. According to previous studies carried out by our group, LNCaP cells are known to 
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harbor low-level amplification of 9p13.3, whereas the copy-number status of PC-3 cells 
is normal. This means that also the LNCaP cells not transfected with UBAP2 might 
express it at moderate level. According to our RT-qPCR results, UBAP2 expression 
level of both LNCaP and PC-3 cells transfected with empty expression vector was 
negligible as compared to the cells transfected with UBAP2. 
6.3 Biological effects of UBAP2 
Even though the overexpression of full-length UBAP2 seems to have a small improving 
effect on the growth rate of prostate cancer cells, we could not point out statistically 
significant difference. It is possible, simply, that function of UBAP2 in the cell has no 
direct effect on mechanisms regulating cell proliferation and thus overexpression of 
UBAP2 in the cells has no apparent effects on the short time scale. Alternatively, 
UBAP2 might effect on a pathway that saturates already at low UBAP2 concentration. 
In that case, extra protein has no impact on this pathway, if the endogenous UBAP2 has 
already saturated it. It is also possible that UBAP2 has an effect on the growth only in 
the presence of some other, thus far unknown factor. However, it is possible that our 
study was unable to find the possible effect of UBAP2. The main reason for this could 
be the overexpression method utilized in this study. Full-length UBAP2 and various 
truncated variants were overexpressed by using transient transfection. In this method, 
transfected DNA is not integrated into the genome of the host cell, but remains as a 
epichromosomal plasmid which is eventually lost from the cell as the cell proliferates. 
Moreover, there was no selection to distinguish non-transfected cells from those that 
have received plasmid. However, transient transfection method is fast and simple to 
perform, and that is why it was selected in the current study. 
According to the results of the fluorescence immunocytochemistry experiments 
conducted in this study, less than half of the cell population transfected with full-length 
UBAP2 actually overexpressed it. It is also commonly known that this is weakness of 
transient transfection. If only a small portion of the population has improved 
proliferation ability, studying the whole population may not reveal it. Another weakness 
of transient transfection method is that transfection reagents are sometimes harmful for 
cells. The transfection process itself affects the viability of the cells, so it is possible 
they do not behave completely normally as without transfection. The bias caused by this 
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effect can be at least partially neutralized by transfecting control cells with empty 
expression vector, as we did. For the reasons presented above, it could be reasonable to 
create stable clones overexpressing UBAP2 in the future studies. 
As opposed to full-length UBAP2, truncated UBAP2 variants inhibited the proliferation 
of PC-3 cells when overexpressed in them, and this effect was statistically significant. 
This seems unexpected, as we hypothesized that truncated UBAP2 variants might have 
partially similar features as full-length protein. The only known functional domain of 
UBAP2, the UBA-domain, is encoded by the exons 3 and 4, and the two of three 
studied truncated variants contain this area. For this reason, it seems unlikely that all of 
the three different UBAP2 variants analyzed in this study would have inhibitory 
features lacking in full-length UBAP2. However, it is possible that these truncated 
variants are misfolded in the cell and overexpression of misfolded proteins itself is a 
burden for the cell. There is the accurate protein degradation mechanism in the cell and 
usually it effectively degrades all the misfolded and damaged proteins preventing them 
to disturb the functions of the cell (Goldberg 2003). If the production of misfolded 
proteins exceed the cell’s degradative capacity, proteins commonly aggregate. These 
protein aggregates are cytotoxic and inhibitory effect of truncated UBAP2 variants 
could arise from this phenomenon.  
As the biological function of UBAP2 is still largely unknown, we can only speculate if 
the truncated UBAP2 proteins have any function in the cells. The results of this study 
do not assess whether the truncated UBAP2 transcripts are translated and expressed at 
the protein level in the cells. If they are translated, it is possible that they fold 
incorrectly and are very short-lived and unstable. In spite of all, if these variants are 
translated and folded, they possibly have same UBA-domain mediated function as full-
length UBAP2 protein, at least partly. However, it is unknown if UBAP2 function is 
dependent on UBA-domain. 
Ubiquitin associated domains (also known as UBA-domains) are functional protein 
domains that are able to bind ubiquitin molecules. Ubiquitin is a small regulatory 
protein, which is in most cases attached to proteins thus labeling them for degradation 
(Su, Lau 2009). This process called ubiquitination regulates a wide range of cellular 
functions in eukaryotes. Attachment of a chain of multiple ubiquitins, polyubiquitin, 
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usually labels proteins for degradation, while the attachment of a single ubiquitin, 
monoubiquitin, is in some cases associated with non-proteolytic functions (Hicke 2001).  
The UBA-domain family was first described by Hofmann and Bucher over 15 years ago 
(Hofmann, Bucher 1996). The length of the primary structure of these domains is about 
45 amino acids. UBA-domains are quite common in proteins. In some cases, the 
biological functions of the UBA-domain containing proteins are well-known, while the 
functions of others are only poorly understood. Generally, proteins containing 
UBA-domain are frequently involved in ubiquitin-dependent signaling pathways. 
UBA-domains can be classified according their binding properties; some of them 
interact strongly with polyubiquitin chains or monoubiquitin molecules, while the others 
interact only with polyubiqitin chains linked to specific molecules. However, there are 
no studies that the UBAP2 protein would have any ubiquitin-dependent functions, but 
due to its UBA-domain this possibility cannot be ruled out. 
The results of the fluorescence immunocytochemistry experiment pointed out that only 
a small portion of transfected cells overexpressed UBAP2, but they also indicate that 
the full-length UBAP2 was highly overexpressed also at protein level. The expressed 
UBAP2 proteins localized predominantly to the cytoplasm. Unfortunately, the lack of 
commercial UBAP2 specific antibodies suitable for western blot prevented us from 
measure UBAP2 protein level expression by this method. The only available anti-
UBAP2-antibody at the time of our study was guaranteed by manufacturer only for 
immunohistochemistry. We tested it also to western blot, but it seemed not to work, as 
results were unreadable and messy. This might result from the fact that proteins are 
denatured for western blotting, unlike in immunocytochemistry. Some antibodies 
recognize only correctly folded target protein, and anti-UBAP2-antibody used in this 
study may belong to this group. Nowadays, at least one new anti-UBAP2-antibody has 
been launched on the market, and it is guaranteed to be applicable to western blot also. 
In the future, it would be reasonable to use it for the detection of UBAP2 in western 
blot. 
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7. CONCLUSION 
The aim of this study was to clone UBAP2 and to explore its role in prostate cancer. 
UBAP2 is a potential target gene of the 9p13.3 chromosomal gain previously identified 
by our group. In this study, we cloned the full-length UBAP2 gene and some of its 
truncated variants. We also identified multiple novel splice variant of UBAP2. In 
addition, we noticed that UBAP2 mRNA seems to be prone to template switching 
artifacts during cDNA synthesis. In the future, there will be a need to determine the 
function of this poorly known gene, which would also open possibilities to understand 
the role of variable splicing. 
The second aim of this study was to analyze the effects UBAP2 overexpression has on 
the proliferation of prostate cancer cells. Our results suggest that full-length UBAP2 
might exhibit a small improving effect on the proliferation of prostate cancer cells. 
However, we cannot conclude from these findings whether UBAP2 is the target gene of 
the 9p13.3 amplification. Further investigations have to be carried out to clarify the role 
of the increased expression of UBAP2 in prostate cancer. Nevertheless, the results of 
this study provide a solid foundation for further studies focusing on the role of UBAP2 
in prostate cancer. 
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